ロード中...
How should we monitor the cardiovascular benefit of sodium–glucose cotransporter 2 inhibition?
Sodium–glucose cotransporter 2 (SGLT2) inhibitors are increasingly prescribed for the treatment of patients with type 2 diabetes to reduce the risk of cardiovascular events, including heart failure (HF). The mechanisms by which SGLT2 inhibitors reduce such risk are likely to be independent of diabet...
保存先:
| 出版年: | Cardiovasc Diabetol |
|---|---|
| 主要な著者: | , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
BioMed Central
2020
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7722318/ https://ncbi.nlm.nih.gov/pubmed/33287812 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12933-020-01191-5 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|